NICE draft recommendation against lenacapavir for PrEP slammed
The British Association for Sexual Health and HIV (BASHH) is deeply disappointed by the UK’s National Institute for Health and Care Excellence’s (NICE) draft recommendation not to approve lenacapavir for HIV prevention in the National Health Service (NHS) in England.
US antivirals specialist Gilead Sciences’ (Nasdaq: GILD) lenacapavir, trade name Yeztugo, is a long-acting option for HIV prevention that requires a 6-monthly injection. Technologies like this have the potential to broaden choice and help address some of the key barriers that prevent people from accessing or consistently using existing forms of PrEP.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze